Neoadjuvant and Adjuvant Durvalumab in Combination With Neoadjuvant Chemotherapy in Patients With Operable Urothelial Cancer.

Urothelial Cancer Clinical Trial

— SAKK 06/17  

Official title:

Neoadjuvant and Adjuvant Durvalumab in Combination With Neoadjuvant Chemotherapy in Patients With Operable Urothelial Cancer. A Multicenter, Single-arm Phase II Trial

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03406650
• Other study ID #: SAKK 06/17
• Secondary ID: 2017-003565-10
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: May 15, 2018
• Est. completion date: April 2026

Study information

• Verified date: August 2023
• Source: Swiss Group for Clinical Cancer Research
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main objective is to demonstrate that the addition of neoadjuvant and adjuvant immunotherapy with durvalumab, to standard neoadjuvant chemotherapy (with cisplatin/gemcitabine) and surgery in urothelial carcinoma could improve event-free survival.

Description:

Despite optimal surgical management the prognosis for localized muscle invasive urothelial cancer (MIUC) is unfavorable with 5-year overall survival of around 45%. According to international guidelines the use of cisplatin-based neoadjuvant chemotherapy is considered standard of care in all patients with localized MIUC with planned curative local treatment. However, the benefit of neoadjuvant chemotherapy is limited and there is a clear medical need for improvement for this patient population. Durvalumab has been tested in a phase I/II open-label study including patients with metastatic urothelial cancer (mUC). The results demonstrated an overall response rate (RR) of 31% in 42 response-evaluable patients. The side effect profile was favorable with most common grade 1/2 AE representing fatigue (13%), diarrhea (10%) and decreased appetite (8%). Three patients (4.9%) had treatment related grade 3 AE's, no grade 4/5 events were noted. The combination of cisplatin/gemcitabine chemotherapy with modern immune-checkpoint inhibition has been demonstrated to be feasible with demonstration of favorable immunomodulatory effects. In view of these data it appears a logical step to apply these novel agents in the curative setting of neoadjuvant treatment. The expected benefit of combining chemotherapy with durvalumab and to continue durvaluamb postoperatively might be twofold: - to increase the response rate in the pre-operative setting and subsequently to increase the rate of pathologic complete remission (pT0) and to reduce risk of local recurrence - to evoke durable systemic anti-cancer responses and subsequently to increase disease free- and overall survival and furthermore to induce antitumor immune response.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 61
• Est. completion date: April 2026
• Est. primary completion date: February 25, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Written informed consent according to ICH/GCP regulations before registration and prior to any trial specific procedures
• Histologically proven urothelial cell carcinoma of the bladder, urethra or upper urinary tract (T2, T3, or T4a and = N1 (defined as a solitary lymph node = 2 cm in the greatest dimension), M0) and be considered suitable for curative multimodality treatment including surgery by a multidisciplinary tumor board. Cytological diagnosis is only allowed for upper tract urothelial carcinoma. In these cases tumor has to be documented by urography
• All histological subtypes eligible if urothelial carcinoma predominant (exception:

small cell component)

• Age = 18 years
• WHO performance status 0-1
• Bone marrow function: hemoglobin = 90 g/L, neutrophil count = 1.5 x 109/L, platelet count = 100 x 109/L
• Hepatic function: bilirubin = 1.5 x ULN (except for patients with Gilbert's disease = 3.0 x ULN), AST = 2.5 x ULN and ALT = 2.5 x ULN, alkaline phosphatase = 2.5 x ULN
• Renal function: estimated glomerular filtration rate (eGFR) > 50 mL/min/1.73m², according to CKD-EPI formula
• Cardiac function: Left ventricular Ejection Fraction (LVEF) = 50% as determined by echocardiography (ECHO)
• Women with child-bearing potential are using effective contraception (for details of definition see 9.9), are not pregnant or lactating and agree not to become pregnant during trial treatment and during 90 days thereafter. A negative pregnancy test before inclusion into the trial is required for all women with child-bearing potential
• Men agree not to father a child during trial treatment and during 90 days thereafter
• Body weight > 30kg.

Exclusion Criteria:

• Any pathological evidence of small-cell carcinoma component
• Presence of any distant metastasis
• History of hematologic or primary solid tumor malignancy, unless in remission for at least 3 years before registration, with the exception of adequately treated cervical carcinoma in situ, localized non-melanoma skin cancer or low risk localized prostate cancer (T1-T2a, Gleason <7, PSA <10ng/ml)
• Any previous treatment with a PD-1 or PD-L1 inhibitor, including durvalumab
• Concurrent treatment with prednisone (or equivalent); except for the prophylactic medication before chemotherapy, treatment of acute hypersensitivity reactions or chronic treatment (initiated > 6 months prior to registration) at low dose (= 10 mg/day of prednisone or an equivalent corticosteroid)
• Concurrent treatment with other experimental drugs or other anticancer therapy, treatment in a clinical trial within 28 days prior to registration
• Current or prior use of immunosuppressive medication within 28 days prior to registration, with the exception of intranasal and inhaled corticosteroids or systemic corticosteroids
• Major surgical procedure within 28 days prior to registration
• Preexisting peripheral neuropathy (> grade 1)
• Uncontrolled diabetes mellitus
• Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc]). The following are exceptions to this

criterion:

• Patients with vitiligo or alopecia
• Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement
• Any chronic skin condition that does not require systemic therapy
• Patients without active disease in the last 5 years may be included but only after consultation with the coordinating investigator
• Patients with celiac disease controlled by diet alone
• Known history of human immunodeficiency virus (HIV) or active chronic Hepatitis C or Hepatitis B Virus infection or any uncontrolled active systemic infection requiring intravenous (iv) antimicrobial treatment
• History of allogeneic organ transplant
• Receipt of live attenuated vaccine within 30 days prior to registration. Note:

Patients, if enrolled, should not receive live vaccine during trial treatment and up to 30 days after the last dose

• Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent
• Any concurrent drug contraindicated for blocking the effect of durvalumab; this includes systemic corticosteroids, methotrexate, azathioprine, and tumor necrosis factor (TNF)-a blockers. Any concurrent drug contraindicated for use with the other trial drugs according to the locally approved product information
• Known hypersensitivity to cisplatin, gemcitabine or durvalumab or to any excipient
• Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of durvalumab.

Related Conditions & MeSH terms

• Urothelial Cancer

Intervention

Drug:
• Neoadjuvant and adjuvant durvalumab
Neoadjuvant durvalumab 1500 mg q3w for 4 cycles Adjuvant durvalumab 1500 mg q4w for 10 cycles

Locations

Country	Name	City	State
Germany	Universitätsklinikum Düsseldorf	Düsseldorf
Germany	Urologische Universitätsklinik Essen	Essen
Switzerland	Kantonspital Aarau	Aarau
Switzerland	Kantonsspital Baden	Baden
Switzerland	Universitaetsspital Basel	Basel
Switzerland	Inselspital	Bern
Switzerland	Kantonsspital Graubünden	Chur
Switzerland	Spital Thurgau AG	Frauenfeld
Switzerland	Hopital Cantonal Universitaire de Geneve	Geneva
Switzerland	Centre Hospitalier Universitaire Vaudois CHUV	Lausanne
Switzerland	Luzerner Kantonsspital	Luzern
Switzerland	Kantonsspital St. Gallen	St. Gallen
Switzerland	Kantonsspital Winterthur	Winterthur
Switzerland	City Hospital Triemli	Zurich
Switzerland	UniversitaetsSpital Zuerich	Zurich
Switzerland	Klinik Hirslanden - Onkozentrum Hirslanden	Zürich
Switzerland	OnkoZentrum Zürich	Zürich

Sponsors (1)

Lead Sponsor	Collaborator
Swiss Group for Clinical Cancer Research

Countries where clinical trial is conducted

Germany,  Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	event-free survival (EFS)	The primary endpoint of the trial is Event-free survival (EFS) at 2 years after neoadjuvant trial treatment start.; Event-free survival is defined as the time from treatment start until one of the following events, whichever comes first: Progression during neoadjuvant treatment leading to inoperability; Recurrence of locoregional disease after surgery; Appearance of metastases at any localization; Death Patients not experiencing an event will be censored at the date of the last available assessment before initiation of a subsequent treatment, if any.	2 years after treatment start
Secondary	Event-free survival (EFS)	Event-free survival is defined as the time from treatment start until one of the following events, whichever comes first: Progression during neoadjuvant treatment leading to inoperability; Recurrence of locoregional disease after surgery; Appearance of metastases at any localization; Death Patients not experiencing an event will be censored at the date of the last available assessment before initiation of a subsequent treatment, if any.	at the occurrence of the event or latest 5 years after surgery
Secondary	Recurrence-free survival (RFS) after R0 resection	RFS after R0 resection is defined as the time from surgery until one of the following events, whichever comes first: Recurrence of locoregional disease; Appearance of metastases at any localization; Death Patients not experiencing an event will be censored at the date of the last available assessment before initiation of a subsequent treatment, if any.; This endpoint will only be calculated for patients in the R0 resection set.	at recurrence or latest 5 years after surgery
Secondary	Overall survival (OS)	Overall survival is defined as the time from treatment start until death from any cause. Patients not experiencing an event will be censored at the last date they were known to be alive.	at death or latest 5 years after surgery
Secondary	Quality of resection	The quality of resection will be assessed in the following way: Complete resection (R0) defined as free resection margins proved microscopically; Completeness of the lymphadenectomy and surgery using the photo documentation and histopathology; Postoperative complications will be assessed using the Clavien-Dindo classification	after surgery or the latest 20 weeks after registration
Secondary	Pathological complete response rate (ypT0)	Pathological complete response (ypT0) is defined as no residual tumor in the surgical specimen. The proportion of patients with ypT0 will be calculated for patients in the resected patients set.	after surgery or the latest 20 weeks after registration
Secondary	Pathological response rate (PaR) defined by pathological downstaging to =ypT1N0M0	Pathological response (PaR) is defined as pathological downstaging to = ypT1N0M0. The proportion of patients with PaR will be calculated for patients in the resected patients set.	after surgery or the latest 20 weeks after registration
Secondary	Pattern of recurrence	Pattern of recurrence is defined as location of first tumor recurrence. Patterns can be locoregional or distant or any combination of these patterns.; Patients with secondary malignancies or patients with no recurrence will not be taken into consideration for this endpoint.	after recurrence or latest 5 years after surgery
Secondary	Treatment feasibility	The following feasibility criteria will be assessed: completion of 4 cycles of neoadjuvant chemotherapy; completion of 4 cycles of neoadjuvant durvalumab treatment; timely admission to and completion of planned surgery; timely initiation and completion of 10 cycles of adjuvant durvalumab treatment	after treatment end or the latest 73 weeks after registration
Secondary	Adverse events	All AEs will be assessed according to NCI CTCAE v4.03	within treatment start and 90 days after last trial treatment and resolution of all related AEs thereafter (at the latest 5 years after surgery)